van den Broek Richard 4

What Happened
Richard van den Broek, a director of Corvus Pharmaceuticals (CRVS), received a derivative award on 2026-06-11 covering 15,000 shares. The grant is reported as an acquisition at $0.00 (i.e., a stock option/award rather than a cash purchase). No exercise price or immediate cash value is shown in the Form 4 — the award represents rights to underlying shares rather than an immediate stock purchase.

Key Details

• Transaction date: 2026-06-11; Form 4 filed 2026-06-15 (timely within SEC two-business-day requirement).
• Transaction type: A (Award/Grant of a derivative instrument) — 15,000 shares reported as acquired at $0.00.
• Shares owned after transaction: not stated in the filing.
• Footnote: The underlying option vests and becomes exercisable 100% on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 annual meeting, assuming continued service as a director.
• No indication of a cashless exercise, sale, tax-withholding, or a 10b5-1 plan in the filing.

Context
This is a compensation-related equity award to a non-employee director (a derivative grant), common in board compensation packages. Because these are unexercised derivative rights (not an open-market buy or sale), they do not reflect an immediate cash outlay or proceeds and should be interpreted as part of routine director compensation rather than a direct bullish or bearish trade.